Levodopa-induced Dyskinesia: Clinical Features, Pathophysiology, and Medical Management

被引:94
|
作者
Pandey, Sanjay [1 ]
Srivanitchapoom, Prachaya [2 ]
机构
[1] Govind Ballabh Pant Postgrad Inst Med Educ & Res, Dept Neurol, Acad Block,Room 507, New Delhi 110002, India
[2] Mahidol Univ, Fac Med, Div Neurol, Dept Med,Siriraj Hosp, Salaya, Nakhon Pathom, Thailand
关键词
Dopamine; dyskinesia; levodopa; Parkinson's disease; NONHUMAN PRIMATE MODEL; PARKINSONS-DISEASE; L-DOPA; MOTOR FLUCTUATIONS; DOUBLE-BLIND; ANTAGONIST ISTRADEFYLLINE; EFFICACY; AMANTADINE; SYMPTOMS; COMPLICATIONS;
D O I
10.4103/aian.AIAN_239_17
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Levodopa-induced dyskinesia (LID) is commonly seen in Parkinson's disease patients treated with levodopa. This side effect is usually encountered after long duration of treatment, but occasionally, this may be seen even after few days or months of treatment. LID is broadly classified as peak-dose dyskinesia, wearing-off or off-period dyskinesia, and diphasic dyskinesia. Pathogenesis of LID is complex, and different neurotransmitters such as dopamine, glutamine, adenosine, and gamma-aminobutyric acid play important role altering the normal physiology of direct and indirect pathway of cortico-basal ganglia-thalamic loop responsible for fine motor control. Treatment of LID requires careful history taking and clinical examination to find the type of dyskinesia as different approach is required for different types. Changes in dopaminergic medication including continuous dopaminergic stimulation are very helpful in the management of peak-dose dyskinesia. Different types of surgical approaches including unilateral pallidotomy and deep brain stimulation have given very good result in patients, who cannot be managed by medications alone. The surgical management of LID is dealt with in detail in another review in this series.
引用
收藏
页码:190 / 198
页数:9
相关论文
共 50 条
  • [31] STUDIES ON PATHOPHYSIOLOGY OF LEVODOPA-INDUCED HYPERSENSITIVITY
    KLAWANS, HL
    HITRI, A
    NAUSIEDA, PA
    WEINER, WJ
    NEUROLOGY, 1978, 28 (04) : 343 - 343
  • [32] Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson's disease
    Nicoletti, Alessandra
    Mostile, Giovanni
    Nicoletti, Giuseppe
    Arabia, Gennarina
    Iliceto, Giovanni
    Lamberti, Paolo
    Marconi, Roberto
    Morgante, Letterio
    Barone, Paolo
    Quattrone, Aldo
    Zappia, Mario
    JOURNAL OF NEUROLOGY, 2016, 263 (05) : 888 - 894
  • [33] Clinical signs associated with levodopa-induced dyskinesia in Parkinson's disease
    Kipfer, S.
    Stephan, M. A.
    Schuepbach, M.
    Kaelin-Lang, A.
    MOVEMENT DISORDERS, 2009, 24 : S267 - S267
  • [34] Chemical management of levodopa-induced dyskinesia in Parkinson's disease patients
    Dragasevic-Miskovic, Natasa
    Petrovic, Igor
    Stankovic, Iva
    Kostic, Vladimir S.
    EXPERT OPINION ON PHARMACOTHERAPY, 2019, 20 (02) : 219 - 230
  • [35] Clinical phenotype and risk of levodopa-induced dyskinesia in Parkinson’s disease
    Alessandra Nicoletti
    Giovanni Mostile
    Giuseppe Nicoletti
    Gennarina Arabia
    Giovanni Iliceto
    Paolo Lamberti
    Roberto Marconi
    Letterio Morgante
    Paolo Barone
    Aldo Quattrone
    Mario Zappia
    Journal of Neurology, 2016, 263 : 888 - 894
  • [36] THE USE OF THALAMOTOMY IN THE TREATMENT OF LEVODOPA-INDUCED DYSKINESIA
    PAGE, RD
    ACTA NEUROCHIRURGICA, 1992, 114 (3-4) : 77 - 117
  • [38] SODIUM VALPROATE IN TREATMENT OF LEVODOPA-INDUCED DYSKINESIA
    PRICE, PA
    PARKES, JD
    MARSDEN, CD
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1978, 41 (08): : 702 - 706
  • [39] A role for serotonergic neurons in levodopa-induced dyskinesia
    Alex Chase
    Nature Reviews Neurology, 2014, 10 (4) : 180 - 180
  • [40] Levodopa-induced dyskinesia in Parkinson's disease
    Brotchie, JM
    Lee, J
    Venderova, K
    JOURNAL OF NEURAL TRANSMISSION, 2005, 112 (03) : 359 - 391